1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676 - 1687

2. Campistol JM, Arias M, Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nephrologia 2013; 33(1): 27 - 45

3. Демьянова К.А. Роль изменений комплемента в развитии поражения почек у больных с микроангиопатическими синдромами: дис. канд. мед. наук: 14.01.29. - М., 2018. - 152 с.

4. Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in thrombotic microangoipathies: unreveling Ariadne's thread into labyrinth of complement therapeutics. Front Immunol 2019; 10: 337. doi: 10.3389/fimmu.2019.00337

5. Greenbaum LA. Atypical hemolytic uremic syndrome. Adv Pediatr 2014; 61(1): 335 - 356

6. Dragon-Durey MA, Sethi SK, Bagga A et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21: 2180 - 2187

7. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8(4): 554 - 562

8. Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of atypical haemolytic uraemic syndrome. J Atheroscler Thromb 2019; 26: 99 - 110. doi: 10.5551/jat.RV17026

9. Rodriguez de Cordoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 2014; 40: 422 - 430. doi: 10.1055/s-0034-1375296

10. Jozsi M, Licht C, Strobel S et al. Factor F autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111: 1512 - 1514

11. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8(11): 622 - 633

12. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med 2013; 24(6): 496 - 502. doi: 10.1016/j.ejim.2013.05.009

13. Riedl M, Fakhouri F, Le Quintrec M et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 2014; 40: 444 - 464

14. Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Hemolytic uremic syndrome. Lancet 2017; 390: 681 - 696. doi: 10.1016/S0140-6736(17)30062-4

15. Cataland SR, Wu HM. Diagnosis and management of complement mediated thrombotic microangiopathies. Blood Rev 2014; 28(2): 67 - 74

16. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6: 60. doi: 10.1186/1750-1172-6-60

17. Yan K, Desai K, Gullapalli L et al. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clinical Epidemiology 2020; 12: 295 - 305

18. Besbas N, Karpman D, Landau, Daniel LC. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, and related disorders. Europian Paediatric Research Group for HUS. Kidney International 2006; 70: 423 - 431

19. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585 - 1594

20. Moake J. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Best Practice&Research Clinical Haematology 2009; 22: 567 - 576

21. Goodship TH, Cook HT, Fakhouri F et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusion from a "Kidney Disease: improving Global Outcomes" (KDIGO) controversies conference. Kidney Int 2017; 91(3): 539 - 551. doi: 10.1016/j.kint.2016.10.005

22. Kato H, Nangaku M, Okada H, Kagami S. Controversies of the classification of TMA and the terminology of aHUS. Clinical and Experimental Nephrology 2017; 22(1). doi: 10.1007/s10157-017-1524-4

23. Le Clech A, Simon-Tillaux N, Provot F et al. Atypical and secondary hemolytic uremic syndrome have a distinct presentation and no common genetic risk factors. Kidney Int 2019; 95: 1443 - 1452. doi: 10.1016/j.kint2019.01.023

24. Praga M, Rodriguez de Cordoba S. Secondary atypical hemolytic uremic syndrome in the era of complement blockade. Kidney Int 2019; 95: 1298 - 1300. doi: 10.1016/j/kint2019.01.043

25. Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 2018; 13: 300 - 317. doi: 10.2215/CJN.00620117

26. Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clinical Kidney Journal 2019; 12(3): 333 - 337. doi: 10.1093/ckj/sfz040

27. M, Ismail K, Fakhouri F et al. Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol 2013; 14(3): 1 - 6

28. Hofer J, Rosales A, Fisher C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Pediatric Nephrol 2014; 2: 1 - 16

29. Swisher KK, Doan JT, Vesely SK et al. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica 2007; 92: 936 - 943

30. Noris M, Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 2014; 10(3): 174 - 180

31. Sallee M, Daniel L, Piercecchi M et al. Myocardial infarction is a complication of factor H associated atypical HUS. Nephrol Dial Transplant 2010; 25: 2028 - 2032

32. Jokiranta S. HUS and atypical HUS. Blood 2017; 21(129): 2847 - 2856

33. Gulleroglu K, Fidan K, VS et al. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 2013; 28(5): 827 - 30. doi: 10.1007/s00467-013-2416-9

34. Кучиева А.М., Козловская Н.Л., Демьянова К.А., Добросмыслов И.А. Рецидивирующий атипичный гемолитико-уремический синдром, манифестировавший поражением поджелудочной железы. Нефрология и диализ 2013; 15(3): 236 - 239

35. Loirat C, Fakhouri F, Ariceta G et al. An international consensus approach to the management of the atypical hemolytic uremic syndrome in chidren. Pediatr Nephrol 2016; 31(1): 15 - 39. doi: 10.1007/s00467-015-3076-8

36. Scully M, Goodship T. How I Treat thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Br J Haematol 2014; 164(6): 759 - 766. doi: 10.1111/bjh.12718

37. Azoulay E, Knoeble P, Garnacho-Montero J et al. Expert Statements on the Standard of Care in Critically Ill Adult Patients with Atypical Hemolytic Uremic Syndrome. Chest 2017; 152(2): 424 - 434

38. Shen YM. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thrombosis Journal 2016; 14(suppl 1): 19. doi: 10.1186/s12959-016-0114-0

39. Cheong HI, Jo SK, Yoon SS et al. Clinical practice guidelines for the management of atypical hemolytic uremic syndrome in Korea. J Korean Med Sci 2016; 31: 1516 - 1528. doi: 10.3346/jkms.2016.31.10.1516

40. Taylor CM, Machin S, Wigmore SJ, Goodship THJ. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. BJH 2009; 148: 37 - 47

41. Kato H, Nangaku M, Hataya H et al. Clinical guides for atypical haemolytic uraemic syndrome in Japan. Clin Exp Nephrol 2016; 20(4): 536 - 543. doi: 10/1007/s10157-016-1276-6

42. Go RS, Winters JL, Leug N et al. Thrombotic microangiopathy care pathway: a consensus statement for the Mayo Clinic complement alternative pathway - thrombotic microangiopathy (CAP-TMA) disease-oriented group. Mayo Clin Proc 2016; 91(9): 1189 - 1211. doi: 10.1016/j.mayocp.2016.05.015

43. Al-Nouri ZL, Reese JA, Terrell DR et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015; 125(4): 616 - 618

44. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129 - 1136

45. Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017; 30(3): 347 - 362. doi: 10.1007/s40620-016-0357-7

46. El-Husseini A, Hannan S, Awad A et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 2015; 65(1): 127 - 130

47. Fakhouri F, Roumenina L, Provot F et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010; 21: 859 - 867

48. Zhang B, Xing C, Yu X et al. Renal thrombotic microangiopathies induced by severe hypertension. Hypertens Res 2008; 31: 479 - 483

49. Timmermans SAMEG, Abdul-Hamid MA, Vanderlocht J et al. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 2017; 91: 1420 - 1425

50. Шевченко Ю.Л., Новик А.А., Мельниченко В.Я. Анемии (руководство по диагностике и лечению). М.: РАЕН, 2012. - 350 с. https://akusher-lib.ru/wp-content/uploads/2019/07/Anemii-rukovodstvo-po-diagnostike-i-lecheniyu.pdf

51. Menne J, Nitschke M, Stingele R et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104: H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 19; 345: e4565. doi: 10.1136/bmj.e4565

52. Shah N, Rutherford C, Matevosyan K et al. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 2013; 163(4): 514 - 9. doi: 10.1111/bjh.12569

53. Bendapudi PK, Li A, Hamdan A et al. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. Br J Haematol 2015; 171(5): 836 - 44. doi: 10.1111/bjh.13658

54. Hassan S, Westwood JP, Ellis D et al. The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry. Br J Haematol 2015; 171(5): 830 - 5. doi: 10.1111/bjh.13654

55. Coppo P, Schwarzinger M, Buffet M et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 2010; 5(4): e10208

56. Cataland SR, Yang S, Wu HM. The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. Br J Haematol 2012; 157(4): 501 - 503

57. Phillips EH, Westwood JP, Brocklebank V et al. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost 2016; 14(1): 175 - 85. doi: 10.1111/jth.13189

58. Wada H, Matsumoto T, Suzuki K et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J 2018; 16: 14. doi: 10.1186/s12959-018-0168-2

59. Lee H, Kang E, Kang HG et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med 2020; 35(1): 25 - 40. doi: 10.3904/kjim.2019.388

60. Lupu F, Keshari RS, Lambris JD, Coggeshall KM. Crosstalk between the coagulation and complement systems in sepsis. Thromb Res 2014; 133(suppl 1): S28 - S31

61. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5(10): 1844 - 1859

62. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8(4): 554 - 62

63. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013; 33: 508 - 530. doi: 10.1016/j.semnephrol.2013.08.003

64. Cataland SR, Holers VM, Geyer S et al. Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP. Blood 2014; 123: 3733 - 3738

65. Noris M, Galbusera M, Gastoldi S et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014; 124: 1715 - 1726

66. Schaefer F, Ardissino G, Ariceta G et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 2018; 94: 408 - 418. doi: 10.1016/j.kint.2018.02.029

67. Jiang H, Fan MN, Yang M et al. Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome. Int J Environ Res Public Health 2016; 13(12): 1209. doi: 10.3390/ijerph13121209

68. KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2: 1 - 138

69. Campistol JM, Arias M, Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nephrologia 2015; 35(5): 421 - 447. doi: 10.1016/j.nefro.2015.07.005

70. De Serres SA, Isenring P. Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. Nephrol Dial Transplant 2009; 24: 1048 - 1050

71. Zuber J, Le Quintrec M, Sberro-Soussan R et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011; 7(1): 23 - 35. doi: 10.1038/nrneph.2010.155

72. Caprioli J, Noris M, Brioschi S et al. International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108(4): 1267 - 1279. doi: 10.1182/blood-2005-10-007252

73. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Seminars in Dialysis 2012; 25(2): 214 - 219. doi: 10.1111/j.1525-139X.2011.01035x

74. Fox LC, Cohney SJ, Kausman JY et al. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Nephrology (Carlton) 2018; 23(6): 507 - 517. doi: 10.1111/nep.13234

75. Michael M, Elliott EJ, Craig JC et al. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 53(2): 259 - 72. doi: 10.1053/j.ajkd.2008.07.038

76. von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 2002; 6(4): 320 - 8. doi: 10.1046/j.1526-0968.2002.00390.x

77. Coppo P, Bussel A, Charrier S et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 2003; 82(1): 27 - 38. doi: 10.1097/00005792-200301000-00003

78. Loirat C, Grnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36: 673 - 681

79. Clark WF, Huang SS, Walsh MW et al. Plasmapheresis for the treatment of kidney diseases. Kidney Int 2016; 90: 974 - 984. doi: 10.1016/j.kint.2016.06.009

80. Schwartz J, Padmanabhan A, Aqui N et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 2016; 31: 149 - 162. doi: 10.1002/jca.21470

81. Claes KJ, Massart A, Collard L et al. Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clin Belg 2018; 73: 80 - 89. doi: 10.1080/17843286.2017.1345185

82. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 1998; 13(1): 16 - 19

83. Zuber J, Fakhouri F, Roumenina LT et al.; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643 - 657. doi: 10.1038/nrneph.2012.214

84. Krishnappa V, Gupta M, Elrifai M et al. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens. Ther Apher Dial 2018; 22(2): 178 - 188. doi: 10.1111/1744-9987.12641

85. Kise T, Fukuyama S, Uehara M. Successful Treatment of Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome. Indian J Nephrol 2020; 30(1): 35 - 38. doi: 10.4103/ ijn.IJN_336_18

86. Sana G, Dragon-Durey MA, Charbit M et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 2014; 29: 75 - 83

87. Cofiell R, Kukreja A, Bedard K et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015; 21; 125(21): 3253 - 62. doi: 10.1182/blood-2014-09-600411

88. Legendre CM, Licht C, Muus PL et al. Terminal complement inhibitor Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169 - 2181. doi: 10.1056/NEJMoa1208981

89. Licht C, Greenbaum LA, Muus P et al. Efficacy and safety of Eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015; 87: 1061 - 1073. doi: 10.1038/ki.2014.423

90. Pugh D, O'Sullivan ED, Duthie FA et al. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021; 3(3): CD012862. doi: 10.1002/14651858

91. Bernuy-Guevara C, Chehade H, Muller YD et al. The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies. Biomedicines 2020; 8(9): 355. doi: 10.3390/biomedicines8090355

92. Menne J, Delmas Y, Fakhouri F et al. Eculizumab prevents thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome in a long-term observational study. Clin Kidney J 2018; 12(2): 196 - 205. doi: 10.1093/ckj/sfy035

93. Menne J, Delmas Y, Fakhouri F et al. Outcome in patients with atypical hemolytic uremic syndrome treated with Eculizumab in a long-term observational study. BMC Nephrology 2019; 20: 125 - 137. doi: 10.1186/s12882-019-1314-1

94. Walle JV, Delmas Y, Ardissino G et al. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 2017; 30(1): 127 - 134. doi: 10.1007/s40620-016-0288-3

95. Ardissino G, Possenti I, Tel F et al. Discontinuation of Eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis 2015; 66: 172 - 173

96. Olson SR, Lu E, Sulpizio E et al. When to stop Eculizumab in complement-mediated microangiopathies. Am J Nephrol 2018; 48: 96 - 107. doi: 10.1159/000492033

97. Клинические рекомендации. Артериальная гипертензия у взрослых. 2024. https://cr.minzdrav.gov.ru/viev-cr/62_4

98. Каабак М.М., Молчанова Е.А., Нестеренко И.В. и др. Резолюция Междисциплинарного совета экспертов. Трансплантация почки у пациентов с атипичным гемолитико-уремическим синдромом: клинические и организационно-методические аспекты ведения пациентов. Нефрология 2018; 3: 8 - 14. doi: 10.18565/nephrology.2018.3.8-14

99. Gonzalez Suarez ML, Thongprayoon C, Mao MA et al. Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis. J Clin Med 2019; 8(7): pii: E919. doi: 10.3390/jcm8070919

100. Siedlecki AM, Isbel N, Vande Walle J et al.; Global aHUS Registry. Eculizumab use for kidney transplantation patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep 2018; 4(3): 434 - 446. doi: 10.1016/j.ekir.2018.11.010

101. Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs 2013; 73(18): 2053 - 66. doi: 10.1007/s40265-013-0147-7

102. Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin Infect Dis 2001; 33(1): 15 - 21. doi: 10.1086/320899

103. Danzinger-Isakov L, Kumar D. AST Infectious Diseases Community of Practice Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9(4): 258 - 262. doi: 10.1111/j.1600-6143.2009.02917.x

104. Резолюция Междисциплинарного совета экспертов по профилактике тяжелых инфекций у пациентов с генетическими нарушениями регуляции системы комплемента, получающих терапию экулизумабом. Эпидемиология и вакцинопрофилактика 2017; 1(92): 51 - 55

105. Bresin E, Daina E, Noris M et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006; 1: 88 - 99. doi: 10.2215/CJN.00050505

106. Keller K, Daniel C, H et al. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol Dial Transplant 2006; 21: 2724 - 2735. doi: 10.1093/ndt/gfl340

107. Nava F, Cappelli G, Mori G et al. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation. Transplant Proc 2014; 46: 2263 - 2268. doi: 10.1016/j.transproceed.2014.07.062

108. Schwimmer J, Nadasdy TA, Spitalnik PF et al. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003; 41: 471 - 479. doi: 10.1053/ajkd.2003.50058

109. Rolla D, Fontana I, Ravetti JL et al. De novo post-transplant thrombotic microangiopathy localized only to the graft in autosomal dominant polycystic kidney disease with thrombophilia. J Renal Inj Prev 2015; 4(4): 135 - 138. doi: 10.12861/jrip.2015.28

110. Zuber J, Le Quintrec M, Krid S et al.; French Study Group for Atypical HUS. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12: 3337 - 3354. doi: 10.1111/j.1600-6143.2012.04252.x

111. Matar D, Naqvi F, Racusen LC et al. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 2014; 98(11): 1205 - 1212. doi: 10.1097/TP.0000000000000200

112. Cugno M, Gualtierotti R, Possenti I et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014; 12: 1440 - 1448

113. Wehling C, Amon O, Bommer M et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 2017; 187(2): 304 - 315. doi: 10.1111/cei.12890

114. Bruel A, Kavanagh D, Noris M et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol 2017; 12(8): 1237 - 1247. doi: 10.2215/CJN.00280117

115. Gupta M, Burwick RM. Pregnancy-associated atypical hemolytic uremic syndrome. A systematic review. Obstetrics&Gynecology 2020; 135: 46 - 58. doi: 10.1097/AOG0000000000003554

116. Grand'Maison S, Lapinsky S. Insights into pregnancy associated and atypical hemolytic uremic syndrome [published correction appears in Obstet Med 2018; 11(4): 198]. Obstet Med 2018; 11(3): 137 - 140. doi: 10.1177/1753495X18780099

117. Коротчаева Ю.В., Козловская Н.Л., Демьянова К.А. и соавт. Генетические аспекты акушерского гемолитико-уремического синдрома. Клиническая нефрология 2017; 1: 12 - 17

118. Huerta A, Arjona E, Portoles J et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int 2018; 93(2): 450 - 459. doi: 10.1016/j.kint.2017.06.022

119. Козловская Н.Л., Коротчаева Ю.В., Шифман Е.М., Кудлай Д.А. Акушерский атипичный гемолитико-уремический синдром: виновата беременность или ее осложнения? Вопросы гинекологии, акушерства и перинатологии 2020; 19(4): 81 - 91. doi: 10.20953/1726-1678-2020-4-81-91

120. Кирсанова Т.В., Виноградова М.А., Федорова Т.А. Имитаторы тяжелой преэклампсии и HELLP-синдрома: различные виды тромботической микроангиопатии, ассоциированной с беременностью. Акушерство и гинекология 2016; 12: 5 - 14. doi: 10.18565/aig.2016.12.5-14

121. Padmanabhan A, Connelly-Smith L, Aqui N et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher 2019; 34(3): 171 - 354. doi: 10.1002/jca.21705

122. Stefanovic V. The Extended Use of Eculizumab in pregnancy and complement activation-associated diseases affecting maternal, fetal and neonatal kidneys - the future is now? J Clin Med 2019; 8(3): 407. doi: 10.3390/jcm8030407

123. Burlinson CEG, Sirounis D, Wally KR, Chau A. Sepsis in pregnancy and the puerperium. Int J Obstet Anesth 2018; 36: 96 - 107. doi: 10.1016/j.ijoa.2018.04.010

124. Nabhan AF, Allam NE, Hamed Abdel-Aziz Salama M. Routes of administration of antibiotic prophylaxis for preventing infection after caesarean section. Cochrane Database Syst Rev 2016; 6: CD011876. doi: 10.1002/14651858.CD011876.pub2

125. Lionet A, F, Glowacki F et al. A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab. NDT Plus 2009; 2(6): 458 - 60. doi: 10.1093/ndtplus/sfp109

126. Breville G, Zamberg I, Sadallah S et al. Case Report: Severe Complement-Mediated Thrombotic Microangiopathy in IgG4-Related Disease Secondary to Anti-Factor H IgG4 Autoantibodies. Front Immunol 2021; 11: 604759. doi: 10.3389/fimmu.2020.604759

127. Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 2019; 26: 99 - 110. doi: 10.5551/jat.RV17026

128. Liu Y, Thaker H, Wang C et al. Diagnosis and Treatment for Shiga Toxin-Producing Escherichia coli Associated Hemolytic Uremic Syndrome. Toxins (Basel) 2022; 15(1): 10. doi: 10.3390/toxins15010010

129. Osborne AJ, Breno M, Borsa NG et al. Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Immunol 2018; 200(7): 2464 - 2478. doi: 10.4049/jimmunol.1701695

130. Valoti E, Alberti M, Iatropoulos P et al. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. Front Immunol 2019; 10: 853. doi: 10.3389/fimmu.2019.00853

131. Bu F, Maga T, Meyer NC et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014; 25(1): 55 - 64. doi: 10.1681/ASN.2013050453

132. Bu F, Zhang Y, Wang K et al. Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018; 29(12): 2809 - 2819. doi: 10.1681/ASN.2018070759

133. Acosta-Medina AA, Moyer AM, Go RS et al. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation. Blood Adv 2023; 7(3): 340 - 350. doi: 10.1182/bloodadvances.2021006416

134. Chaturvedi S, Dhaliwal N, Hussain S et al. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv 2021; 5: 1504 - 1512

135. Fakhouri F, Fila M, Hummel A et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 2021; 137: 2438 - 2449

136. Bouwmeester R, Duinveld C, Wijnsma KL et al. Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study. Kidney Int Rep 2022; 8: 91 - 102

137. Piras R, Valoti E, Alberti M et al. CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome. Front Immunol 2023; 13: 1011580. doi: 10.3389/fimmu.2022.1011580

138. Rondeau E, Scully M, Ariceta G et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome to complement inhibitor treatment. Kidney Int 2020; 97(6): 1287 - 1296. doi: 10.1016/j.kint.2020.01.035

139. Olson SR, Lu E, Sulpizio E et al. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. Am J Nephrol 2018; 48(2): 96 - 107. doi: 10.1159/000492033

140. A, Cao M, Espinosa M et al. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Front Med (Lausanne) 2023: 10: 1264310. doi: 10.3389/fmed.2023.1264310

141. Alberti M, Valoti E, Piras R et al. Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. Am J Transplant 2013; 13: 2201 - 2206. doi: 10.1111/ajt.12297

142. Dowen F, Wood K, Brown AL et al. Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential. Clin Kidney J 2017; 10(4): 490 - 493. doi: 10.1093/ckj/sfx030

143. Korzycka J, E, Masajtis-Zagajewska A, Nowicki M. Novel Complement Factor B Gene Mutation Identified in a Kidney Transplant Recipient with a Shiga Toxin-Triggered Episode of Thrombotic Microangiopathy. Am J Case Rep 2022; 28: 23: e936565. doi: 10.12659/AJCR.936565

144. Tang ZC, Hui H, Shi C, Chen X. New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses. Ren Fail 2023; 45(1): 2231264. doi: 10.1080/0886022X.2023.2231264

145. Duineveld C, Bouwmeester RN, Wijnsma KL et al. Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation. Kidney Int Rep 2023; 8(4): 715 - 726. doi: 10.1016/j.ekir.2023.01.016

146. Barbour T, Scully M, Ariceta G et al. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. Kidney Int Rep 2021; 6(6): 1603 - 1613. doi: 10.1016/j.ekir.2021.03.884

147. Schmidt T, M, Mahmud M et al. Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome. Transplant Direct 2022; 8(2): e1289. doi: 10.1097/TXD.0000000000001289

148. Jehn U, Altuner U, H, Reuter S. First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient. Transpl Int 2022: 35: 10846. doi: 10.3389/ti.2022.10846

149. Fakhouri F, Scully M, Provo F et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood 2020; 136(19): 2103 - 2117. doi: 10.1182/blood.2020005221

150. A, U, Dobronravov V et al. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. BMC Nephrol 2021; 22(1): 5. doi: 10.1186/s12882-020-02190-0

151. Kelly RJ, Hochsmann B, Szer J et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2015; 373: 1032 - 1039. doi: 10.1056/NEJMoa1502950

152. Sarno L, Tufano A, Maruotti GM et al. Eculizumab in pregnancy: a narrative overview. J Nephrol 2019; 32: 17 - 25. doi: 10.1007/s40620-018-0517-z

153. Burwick RM, Burwick N, Feinberg BB. Response: maternal and cord C5a in response to eculizumab. Blood 2015; 126: 279 - 280. doi: 10.1182/blood-2015-06-642553

154. Коротчаева Ю.В., Козловская Н.Л., Шифман Е.М., Моисеев С.В. Экулизумаб в лечении атипичного гемолитико-уремического синдрома, связанного с беременностью: ретроспективное исследование у 85 пациенток. Клиническая фармакология и терапия 2023; 32(3): 36 - 43. doi: 10.32756/0869-5490-2023-3-36-43

155. Servais A, Devillard N, Fremeaux-Bacchi V et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant 2016; 31(12): 2122 - 2130. doi: 10.1093/ndt/gfw314

156. Che M, Moran SM, Smith RJ et al. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy. Kidney International 2024; 105: 960 - 970. doi: 10.1016/j.kint.2023.12.021

157. Abe T, Sasaki A, Ueda T et al. Complement-mediated thrombotic microangiopathy secondary to sepsis induced disseminated intravascular coagulation successfully treated with eculizumab: A case report. Medicine (Baltimore) 2017; 96(6): e6056, doi: 10.1097/MD.0000000000006056

158. Коротчаева Ю.В., Козловская Н.Л., Шифман Е.М. Акушерский атипичный гемолитико-уремический синдром и сепсис: есть ли связь? Тромбоз, гемостаз и реология 2022; 3: 62 - 73. doi: 10.25555/THR.2022.3.1031

159. Брико Н.И., Намазова-Баранова Л.С., Королева И.С. и др. Резолюция Междисциплинарного совета экспертов по профилактике тяжелых инфекций у пациентов с генетическими нарушениями регуляции системы комплемента, получающих терапию экулизумабом. Эпидемиология и вакцинопрофилактика. 2017; 16(1): 51 - 54

160. Levi C, V, Zuber J et al. Transplantation. 2017; 101(12): 2924 - 2930. doi: 10.1097/TP.0000000000001909

161. Midterm outcomes of 12 renal transplant recipients treated with eculizumab to prevent atypical hemolytic syndrome recurrence.

162. Glover EK, Smith-Jackson K, Brocklebank V. et al. Assessing the impact of prophylactic eculizumab on renal graft survival in atypical hemolytic uremic syndrome. Transplantation. 2023; 107(4): 994 - 1003. doi: 10.1097/TP.0000000000004355

163. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev 2011; (10): CD003236. doi: 10.1002/14651858.CD003236.pub2

164. Intiso D, Di Rienzo F, Russo M et al. Rehabilitation strategy in the elderly. J Nephrol 2012; 25 Suppl 19: S90 - 5. doi: 10.5301/jn.5000138

165. F Fakhouri, N Schwotzer, V Fremeaux-Bacchi. How I diagnose and treat atypical hemolytic uremic syndrome. Blood 2023; 141(9): 984 - 995